BIND sunk 52% since a high on November 19 to a low on January 7 as traders lost interest in the micro-cap despite compelling data and upcoming clinical trial catalyst. BIND Therapeutics is a small biotech company developing Accurins, a revolutionary targeted nanomedicine platform.
